2 unknown, 1 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
Follow Humanitas Mirasole SpA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Synthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case Generate synthetic multimodal (clinical, omics and imaging) data for rare haematological diseases with a validated clinical result - Sickle Cell Disease | Active not recruiting | Hospital Universitari Vall d'Hebron Research Institute | 1500 | 2022-11-01 | 2025-03-12 | |
| Open Label Extension of TUDCA-ALS Study Tauroursodeoxycholic Acid - Amyotrophic Lateral Sclerosis | Phase 3 | Unknown | Humanitas Mirasole SpA | 184 | 2021-10-25 | 2023-03-03 |
| Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS Tauroursodeoxycholic Acid, Placebo - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Unknown | Humanitas Mirasole SpA | 337 | 2019-02-22 | 2023-07-10 |
Amyotrophic Lateral Sclerosis (2) · Anemia, Sickle Cell (1)
ursodoxicoltaurine (2) · X-Rays (1)
Italy (3) · Netherlands (3) · Belgium (2) · France (2) · Germany (2) · Ireland (2) · United Kingdom (2) · Spain (1)
2018 (1)